Stifel Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $98

Benzinga Newsdesk www.benzinga.com Positive 60.7%

Neg 0% Neu 0% Pos 60.7%

Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $98.